Rio De Janeiro, RIO%20DE%20JANEIRO2 Active Studies

Geographic Atrophy Clinical Trials in Rio De Janeiro, RIO%20DE%20JANEIRO

Find 2 actively recruiting geographic atrophy clinical trials in Rio De Janeiro, RIO%20DE%20JANEIRO. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
205
Enrolling

Recruiting Geographic Atrophy Studies in Rio De Janeiro

About Geographic Atrophy Clinical Trials in Rio De Janeiro

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 2 geographic atrophy clinical trials recruiting participants in Rio De Janeiro, RIO%20DE%20JANEIRO. These studies are seeking a combined 205 participants. Research is being sponsored by Novartis Pharmaceuticals, Azafaros A.G.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Rio De Janeiro — FAQ

Are there geographic atrophy clinical trials in Rio De Janeiro?

Yes, there are 2 geographic atrophy clinical trials currently recruiting in Rio De Janeiro, RIO%20DE%20JANEIRO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rio De Janeiro?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rio De Janeiro research site will contact you about next steps.

Are clinical trials in Rio De Janeiro free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rio De Janeiro studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 2 active trials in Rio De Janeiro are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov